Merus kündigt Präsentation der klinischen Daten der Phase I für MCLA-158 auf dem „2021 Gastrointestinal Cancers Symposium“ der American Society of Clinical Oncology (ASCO) an

Ads

You May Also Like

Merit Medical to Participate at Six Conferences

BTIG – March 1Raymond James – March 7Barclays – March 15Oppenheimer – March 21Needham – ...

NeoGenomics Schedules its Second Quarter Earnings Release for July 24, 2018

FT. MYERS, Fla., July 02, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ:NEO), a leading ...

aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports ...